SG10201914111XA - 5-substituted indazole-3-carboxamides and preparation and use thereof - Google Patents
5-substituted indazole-3-carboxamides and preparation and use thereofInfo
- Publication number
- SG10201914111XA SG10201914111XA SG10201914111XA SG10201914111XA SG10201914111XA SG 10201914111X A SG10201914111X A SG 10201914111XA SG 10201914111X A SG10201914111X A SG 10201914111XA SG 10201914111X A SG10201914111X A SG 10201914111XA SG 10201914111X A SG10201914111X A SG 10201914111XA
- Authority
- SG
- Singapore
- Prior art keywords
- carboxamides
- preparation
- substituted indazole
- indazole
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461968350P | 2014-03-20 | 2014-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201914111XA true SG10201914111XA (en) | 2020-03-30 |
Family
ID=54141450
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201914111XA SG10201914111XA (en) | 2014-03-20 | 2015-03-20 | 5-substituted indazole-3-carboxamides and preparation and use thereof |
SG11201607816UA SG11201607816UA (en) | 2014-03-20 | 2015-03-20 | 5-substituted indazole-3-carboxamides and preparation and use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201607816UA SG11201607816UA (en) | 2014-03-20 | 2015-03-20 | 5-substituted indazole-3-carboxamides and preparation and use thereof |
Country Status (16)
Country | Link |
---|---|
US (2) | US9745271B2 (en) |
EP (1) | EP3119393A4 (en) |
JP (1) | JP6586104B2 (en) |
KR (1) | KR20160135283A (en) |
CN (1) | CN106535890A (en) |
BR (1) | BR112016021626A2 (en) |
CA (1) | CA2942687A1 (en) |
CL (1) | CL2016002364A1 (en) |
IL (1) | IL247713A0 (en) |
MA (1) | MA39763A (en) |
MX (1) | MX2016012208A (en) |
PE (1) | PE20170127A1 (en) |
PH (1) | PH12016501835A1 (en) |
RU (1) | RU2016141088A (en) |
SG (2) | SG10201914111XA (en) |
WO (1) | WO2015143380A1 (en) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20141678A1 (en) | 2011-09-14 | 2014-11-21 | Samumed Llc | INDAZOL-3-CARBOXAMIDES AND THEIR USE AS INHIBITORS OF THE WNT / B-CATENIN SIGNALING PATHWAY |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
MX370487B (en) | 2013-01-08 | 2019-12-16 | Samumed Llc | 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof. |
SG10201914111XA (en) | 2014-03-20 | 2020-03-30 | Samumed Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
WO2017023988A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017024003A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10226448B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
US10350199B2 (en) | 2015-08-03 | 2019-07-16 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
US10166218B2 (en) | 2015-08-03 | 2019-01-01 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
WO2017023980A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
WO2017023986A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017024010A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
US10206908B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
WO2017024004A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017024025A1 (en) | 2015-08-03 | 2017-02-09 | Sunil Kumar Kc | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017024015A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10392383B2 (en) | 2015-08-03 | 2019-08-27 | Samumed, Llc | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US11033539B2 (en) | 2015-11-06 | 2021-06-15 | Neurocrine Biosciences, Inc. | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases |
BR112018009252A2 (en) | 2015-11-06 | 2018-11-06 | Samumed Llc | osteoarthritis treatment |
EA039638B1 (en) * | 2016-01-06 | 2022-02-21 | Нейрокрин Байосайенсиз, Инк. | Muscarinic receptor 4 antagonists and methods of using same |
WO2017181087A1 (en) * | 2016-04-15 | 2017-10-19 | Felicitex Therapeutics, Inc. | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
AU2017248762A1 (en) * | 2016-04-15 | 2018-11-01 | Felicitex Therapeutics, Inc. | Combinations for the treatment of neoplasms using quiescent cell targeting and EGFR inhibitors |
AR108326A1 (en) | 2016-04-27 | 2018-08-08 | Samumed Llc | ISOQUINOLIN-3-IL CARBOXAMIDS AND PREPARATION AND USE OF THE SAME |
AR108325A1 (en) | 2016-04-27 | 2018-08-08 | Samumed Llc | ISOQUINOLIN-3-IL CARBOXAMIDS AND PREPARATION AND USE OF THE SAME |
SI3464285T1 (en) | 2016-06-01 | 2023-02-28 | Biosplice Therapeutics, Inc. | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo(4,5-c)pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide |
RU2742771C2 (en) | 2016-08-31 | 2021-02-10 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Oxopicolinamide derivative, a method for production thereof and pharmaceutical use thereof |
AU2017345699A1 (en) | 2016-10-21 | 2019-05-16 | Samumed, Llc | Methods of using indazole-3-carboxamides and their use as Wnt/B-catenin signaling pathway inhibitors |
WO2018085865A1 (en) | 2016-11-07 | 2018-05-11 | Samumed, Llc | Single-dose, ready-to-use injectable formulations |
KR102279347B1 (en) * | 2016-12-15 | 2021-07-21 | 한국생명공학연구원 | Pharmaceutical composition for prevention and treatment of DYRK related diseases comprising pyridine compounds |
KR101924801B1 (en) * | 2017-08-16 | 2018-12-04 | 한국원자력의학원 | Composition for preventing or treating cancer comprising triazolopyridine derivatives |
BR112020003292A2 (en) | 2017-08-16 | 2020-08-18 | Vanderbilt University | indazole compounds as allosteric potentiators of mglur4 and their therapeutic uses, as well as pharmaceutical composition and method for the manufacture of medication to enhance the activity of the mglur4 receptor |
KR102179406B1 (en) * | 2017-10-17 | 2020-11-16 | 한국화학연구원 | Novel indazole derivatives, and use thereof |
EP3755696B1 (en) | 2018-02-23 | 2023-04-05 | BioSplice Therapeutics, Inc. | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
EA202092422A1 (en) * | 2018-05-07 | 2021-02-12 | Ацьенде Кимике Рьюните Анджелини Франческо - А.К.Р.А.Ф. С.П.А. | 1H-INDAZOL-3-CARBOXAMIDE COMPOUNDS AS INHIBITORS OF 3-BETA GLYCOGENSINTASE KINASE |
US20230000842A1 (en) * | 2019-01-17 | 2023-01-05 | Samumed, Llc | Methods of treating cartilage disorders through inhibition of clk and dyrk |
WO2020150545A1 (en) * | 2019-01-17 | 2020-07-23 | Samumed, Llc | Pyrazole derivatives as modulators of the wnt/b-catenin signaling pathway |
KR102650856B1 (en) * | 2019-12-16 | 2024-03-25 | 한국화학연구원 | Novel indazole derivatives and use thereof |
CN114230565B (en) * | 2020-09-09 | 2023-10-27 | 成都奥睿药业有限公司 | 5-substituted indole 3-amide derivative, preparation method and application thereof |
EP4221700A1 (en) * | 2020-09-30 | 2023-08-09 | Bioverativ Therapeutics Inc. | Ampk activators and methods of use thereof |
CN115353512A (en) * | 2021-07-30 | 2022-11-18 | 上海翊石医药科技有限公司 | Heterocyclic urea compound and preparation method and application thereof |
CN113735798B (en) * | 2021-09-27 | 2022-07-12 | 安徽美致诚药业有限公司 | Preparation method of roxatidine acetate hydrochloride |
WO2023098699A1 (en) * | 2021-12-01 | 2023-06-08 | Nanjing Immunophage Biotech Co., Ltd | Compounds and their uses as cd38 inhibitors |
US20240132464A1 (en) * | 2022-09-28 | 2024-04-25 | Accutar Biotechnology Inc. | Heterocyclic compounds as e3 ligase inhibitors |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
GB9414139D0 (en) | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Novel compounds |
US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
DE19853299C2 (en) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Catheter for the application of medication in fluid spaces of the human inner ear |
US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
IL164209A0 (en) | 2002-05-31 | 2005-12-18 | Eisai Co Ltd | Pyrazole derivatives and pharmaceutical compositions containing the same |
GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
PL210065B1 (en) | 2002-09-25 | 2011-11-30 | Memory Pharm Corp | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
FR2845382A1 (en) * | 2002-10-02 | 2004-04-09 | Sanofi Synthelabo | INDAZOLECARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS |
US20040197264A1 (en) | 2003-04-04 | 2004-10-07 | Alexander Schwarz | Microspheres comprising therapeutic and diagnostic radioactive isotopes |
WO2005014554A1 (en) | 2003-08-08 | 2005-02-17 | Astex Therapeutics Limited | 1h-indazole-3-carboxamide compounds as mapkap kinase modulators |
EP1532980A1 (en) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
FR2867778B1 (en) * | 2004-03-16 | 2006-06-09 | Sanofi Synthelabo | USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT AND PREVENTION OF MALARIA |
AU2005227324A1 (en) | 2004-03-25 | 2005-10-06 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
EP1827422A2 (en) | 2004-11-23 | 2007-09-05 | Celgene Corporation | Jnk inhibitors for the treatment of cns injury |
EP1861161A4 (en) | 2005-01-24 | 2012-05-16 | Neurosystec Corp | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
SG165417A1 (en) | 2005-09-23 | 2010-10-28 | Memory Pharm Corp | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
AR057987A1 (en) | 2005-11-24 | 2008-01-09 | Astrazeneca Ab | CB1 AGONIST COMPOUNDS (CANNABINOID RECEPTOR) |
US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
EP2167491A1 (en) | 2007-06-08 | 2010-03-31 | Abbott Laboratories | 5-heteroaryl substituted indazoles as kinase inhibitors |
MX2010009462A (en) * | 2008-02-29 | 2010-09-24 | Pfizer | Indazole derivatives. |
DK2987487T3 (en) * | 2009-08-10 | 2020-12-07 | Samumed Llc | INDAZOLINE INHIBITORS OF THE WNT SIGNAL ROAD AND ITS THERAPEUTIC USES |
WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
EP3305073B1 (en) * | 2009-12-21 | 2019-05-15 | Samumed, LLC | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
AR081626A1 (en) * | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS |
IT1402028B1 (en) | 2010-10-14 | 2013-08-28 | Gsi Geosyntec Invest B V | METHOD AND DEVICE FOR DRAINAGE OF INFILTRATED WATER IN HYDRAULIC STRUCTURES. |
PE20141678A1 (en) * | 2011-09-14 | 2014-11-21 | Samumed Llc | INDAZOL-3-CARBOXAMIDES AND THEIR USE AS INHIBITORS OF THE WNT / B-CATENIN SIGNALING PATHWAY |
DE102011087651A1 (en) | 2011-12-02 | 2013-06-06 | Siemens Aktiengesellschaft | Switchgear tripping device |
PL2817302T3 (en) | 2012-02-21 | 2016-06-30 | Acraf | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
PH12017500997A1 (en) * | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
SG10201914111XA (en) | 2014-03-20 | 2020-03-30 | Samumed Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
WO2015140304A1 (en) | 2014-03-20 | 2015-09-24 | Inflarx Gmbh | Inhibitors of c5a for the treatment of viral pneumonia |
WO2015140195A1 (en) | 2014-03-20 | 2015-09-24 | Bayer Pharma Aktiengesellschaft | Novel compounds |
CR20160432A (en) | 2014-03-20 | 2017-07-21 | Bayer Pharma AG | WNT SIGNALING ROAD INHIBITORS |
-
2015
- 2015-03-20 SG SG10201914111XA patent/SG10201914111XA/en unknown
- 2015-03-20 CN CN201580026082.XA patent/CN106535890A/en active Pending
- 2015-03-20 PE PE2016001658A patent/PE20170127A1/en unknown
- 2015-03-20 EP EP15765201.7A patent/EP3119393A4/en not_active Ceased
- 2015-03-20 JP JP2016558073A patent/JP6586104B2/en active Active
- 2015-03-20 MA MA039763A patent/MA39763A/en unknown
- 2015-03-20 MX MX2016012208A patent/MX2016012208A/en unknown
- 2015-03-20 US US14/664,517 patent/US9745271B2/en active Active
- 2015-03-20 SG SG11201607816UA patent/SG11201607816UA/en unknown
- 2015-03-20 WO PCT/US2015/021847 patent/WO2015143380A1/en active Application Filing
- 2015-03-20 BR BR112016021626-1A patent/BR112016021626A2/en not_active Application Discontinuation
- 2015-03-20 KR KR1020167028641A patent/KR20160135283A/en unknown
- 2015-03-20 RU RU2016141088A patent/RU2016141088A/en not_active Application Discontinuation
- 2015-03-20 CA CA2942687A patent/CA2942687A1/en not_active Abandoned
-
2016
- 2016-09-08 IL IL247713A patent/IL247713A0/en unknown
- 2016-09-20 CL CL2016002364A patent/CL2016002364A1/en unknown
- 2016-09-20 PH PH12016501835A patent/PH12016501835A1/en unknown
-
2017
- 2017-07-19 US US15/653,747 patent/US10669240B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20150266825A1 (en) | 2015-09-24 |
CN106535890A (en) | 2017-03-22 |
EP3119393A1 (en) | 2017-01-25 |
PH12016501835A1 (en) | 2017-01-09 |
MA39763A (en) | 2017-01-25 |
KR20160135283A (en) | 2016-11-25 |
WO2015143380A1 (en) | 2015-09-24 |
RU2016141088A3 (en) | 2018-11-20 |
SG11201607816UA (en) | 2016-10-28 |
US10669240B2 (en) | 2020-06-02 |
US20180127377A1 (en) | 2018-05-10 |
CA2942687A1 (en) | 2015-09-24 |
CL2016002364A1 (en) | 2017-06-23 |
BR112016021626A2 (en) | 2018-05-15 |
EP3119393A4 (en) | 2018-02-28 |
MX2016012208A (en) | 2017-01-26 |
JP2017508763A (en) | 2017-03-30 |
US9745271B2 (en) | 2017-08-29 |
RU2016141088A (en) | 2018-04-25 |
JP6586104B2 (en) | 2019-10-02 |
PE20170127A1 (en) | 2017-03-30 |
IL247713A0 (en) | 2016-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL247713A0 (en) | 5-substituted indazole-3-carboxamides and preparation and use thereof | |
HK1255067A1 (en) | Anti-c10orf54 antibodies and uses thereof | |
HK1243440A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
IL247407A0 (en) | Anti-egfrviii antibodies and uses thereof | |
HK1231471A1 (en) | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof 6-- 6--2- | |
GB201519858D0 (en) | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof | |
GB201411197D0 (en) | Composition and use thereof | |
HUE060941T2 (en) | Haloolefin-based composition and use thereof | |
PL3152226T3 (en) | Modified cyclopentapeptides and uses thereof | |
HK1232169A1 (en) | Substituted 4-phenylpiperidines, their preparation and use 4- | |
GB201401617D0 (en) | Novel combination and use | |
IL247315A0 (en) | Anti-acth antibodies and use thereof | |
SG11201609490QA (en) | Polymer-flavonoid conjugate and uses thereof | |
HK1243950A1 (en) | Novel combination and use | |
IL251001B (en) | Anti-il-25 antibodies and uses thereof | |
HK1243077A1 (en) | Piperidinylpyrazolopyrimidinones and their use | |
GB201411196D0 (en) | Composition and use thereof | |
PL3129398T3 (en) | New medical agents and uses thereof | |
SG11201700191PA (en) | Microbiocides and uses thereof | |
GB2545167B (en) | Cloches and use thereof | |
PL3229772T3 (en) | 6-aryl-9-glycosylpurines and use thereof | |
AU2015230999A1 (en) | 5-substituted indazole-3-carboxamides and preparation and use thereof | |
GB201500278D0 (en) | Novel combination and use | |
GB201413411D0 (en) | Novel compounds and their use | |
GB201404728D0 (en) | Disc-over incorporating disc-heads and disc-earning |